Skip to main navigation
Logo

SEC Filings

SEC Filings

Filing date Form Description View
Nov 2, 2020 4

Statement of changes in beneficial ownership of securities

View HTML
0001209191-20-056428.pdf
0001209191-20-056428.xls
Oct 30, 2020 3

Initial filing by director officer or owner of more than ten percent.

View HTML
0001209191-20-056343.pdf
0001209191-20-056343.xls
Oct 30, 2020 4

Statement of changes in beneficial ownership of securities

View HTML
0001209191-20-056344.pdf
0001209191-20-056344.xls
Oct 29, 2020 424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

View HTML
0001193125-20-281028.pdf
0001193125-20-281028.xls
Oct 28, 2020 424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

View HTML
0001193125-20-279186.pdf
0001193125-20-279186.xls
Oct 27, 2020 8-K

Report of unscheduled material events or corporate event

View HTML
0000950170-20-000093.pdf
0000950170-20-000093.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Oct 27, 2020 10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML
0001564590-20-047991.pdf
0001564590-20-047991.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Oct 26, 2020 8-K

Report of unscheduled material events or corporate event

View HTML
0000950170-20-000088.pdf
0000950170-20-000088.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Oct 23, 2020 8-K

Report of unscheduled material events or corporate event

View HTML
0000950170-20-000085.pdf
0000950170-20-000085.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Oct 16, 2020 4

Statement of changes in beneficial ownership of securities

View HTML
0001209191-20-055172.pdf
0001209191-20-055172.xls

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »
Investors

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • Investor FAQ
    • Contact Us

    Shareholder Tools

    • Email Alerts
    • Print
    • Share

  • Facebook
  • LinkedIn
  • Twitter
  • RSS
  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Jayson Dallas, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
    • Grants & Charitable Contributions
    • Our Commitment to Patients
    • Message from BIO
  • Medicines
    • Crysvita®
    • Mepsevii®
    • Dojolvi®
    • Dojolvi™ for Canada
    • DojolviMC–Français Canadien
  • Pipeline
    • DTX 301 for OTC
    • DTX 401 for GSDIa
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • OTC
    • GSD1a
    • Access to Approved Therapies
    • Access to Investigational Therapies
  • Investors

      Investors

      • Press Releases
      • Events & Presentations
      • Corporate Governance
      • SEC Filings
      • Stock Information
      • Analyst Coverage
      • Investor FAQ
      • Contact Us
  • Careers
    • Culture
    • Benefits
    • Talent Network
    • Jobs
  • Partnering
    • Current Partnerships
  • Contact
  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Jayson Dallas, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
    • Grants & Charitable Contributions
    • Our Commitment to Patients
    • Message from BIO
    • Medicines
      • Crysvita®
      • Mepsevii®
      • Dojolvi®
      • Dojolvi™ for Canada
      • DojolviMC–Français Canadien
  • Pipeline
    • DTX 301 for OTC
    • DTX 401 for GSDIa
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • OTC
    • GSD1a
    • Access to Approved Therapies
    • Access to Investigational Therapies
  • Investors

      Investors

      • Press Releases
      • Events & Presentations
      • Corporate Governance
      • SEC Filings
      • Stock Information
      • Analyst Coverage
      • Investor FAQ
      • Contact Us
  • Careers
    • Culture
    • Benefits
    • Talent Network
    • Jobs
    Partnering
    • Current Partnerships
    Contact
    • Driving Directions
  • Privacy Policy
© 2021 Ultragenyx Pharmaceutical Inc.Website Design: Hane Chow, Inc.
  • Privacy Policy
  • Cookie Policy